<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04573543</url>
  </required_header>
  <id_info>
    <org_study_id>UHID-05</org_study_id>
    <nct_id>NCT04573543</nct_id>
  </id_info>
  <brief_title>The Role of Immune Semaphorins in NAFLD</brief_title>
  <acronym>SepsisFAT</acronym>
  <official_title>The Role of Immune Semaphorins in NAFLD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital for Infectious Diseases, Croatia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Croatian Science Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital for Infectious Diseases, Croatia</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To goal is to identify semaphorins that are associated with NAFLD and to investigate their&#xD;
      relationship with variable degrees of steatosis and fibrosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease associated&#xD;
      with systemic changes in immune response. Semaphorins were recently recognized as one of the&#xD;
      key regulators of immune responses; while some suppress immune cells activation,&#xD;
      proliferation, and production of inflammatory cytokines, others stimulate immune responses.&#xD;
      We have previously shown that semaphorins are associated with pathogenesis of viral hepatitis&#xD;
      and progression of fibrosis. However, their role in NAFLD is unknown. The hypothesis of this&#xD;
      project is that semaphorins are regulators of inflammation in patients with NAFLD. This study&#xD;
      is designed as a prospective, non-interventional study. The main aims are: (1) to analyze&#xD;
      serum concentration of semaphorins in patients with NAFLD; (2) to analyze tissue expression&#xD;
      of semaphorins in patients with NAFLD; (3) to analyze semaphorin gene polymorphisms&#xD;
      associated with NAFLD. Semaphorins could be a novel diagnostic and prognostic biomarker as&#xD;
      well as targets for immune modulation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2020</start_date>
  <completion_date type="Anticipated">March 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Detection of semaphorins in patients with NAFLD</measure>
    <time_frame>12 months</time_frame>
    <description>Measurement of semaphorins concentration in serum of patients with NAFLD by enzyme-linked immunosorbent assay (ELISA)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Identification of semaphorin gene polymorphism in patients with NAFLD</measure>
    <time_frame>12 months</time_frame>
    <description>Sequencing of semaphorin genes in patients with NAFLD using Sanger sequencing</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Staging of liver steatosis</measure>
    <time_frame>12 months</time_frame>
    <description>The degree of steatosis will be estimated using the controlled attenuation parameter (CAP) in patients with NAFLD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Staging of liver fibrosis</measure>
    <time_frame>12 months</time_frame>
    <description>The stage of liver fibrosis will be assessed by transient elastography (TE) in patients with NAFLD</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Non-Alcoholic Fatty Liver Disease</condition>
  <condition>Immune Response</condition>
  <condition>Biomarkers</condition>
  <condition>Liver Fibrosis</condition>
  <condition>Non Alcoholic Steatohepatitis</condition>
  <arm_group>
    <arm_group_label>Patients with Non-alcoholic fatty liver disease</arm_group_label>
    <description>120 patients diagnosed with NAFLD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controls</arm_group_label>
    <description>40 healthy controls</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Evaluation of the degree of fibrosis and steatosis</intervention_name>
    <description>The degree of steatosis will be estimated using the controlled attenuation parameter (CAP), a method for grading steatosis by measuring the degree of ultrasound attenuation by hepatic fat using a process based on simultaneous transient elastography (TE) which measures the degree of fibrosis.</description>
    <arm_group_label>Controls</arm_group_label>
    <arm_group_label>Patients with Non-alcoholic fatty liver disease</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Screening for the components of metabolic syndrome</intervention_name>
    <description>Anthropometric measures including body mass index (BMI), waist circumference (WC), waist hip ratio (WHR), and waist height ratio (WHtR) will be measured in all patients.&#xD;
Results of the routine laboratory tests as part of the standard diagnostic procedure will be collected: bilirubin, AST, ALT, GGT, ALP, albumins, WBC, neutrophil-to-lymphocyte ratio, hemoglobin, platelet count, fasting glucose, triglycerides, cholesterol, HDL and LDL. Non-invasive scores of steatosis/fibrosis will be calculated (APRI, FIB4, NAFLD score). Patients will be screened for the components of metabolic syndrome.</description>
    <arm_group_label>Controls</arm_group_label>
    <arm_group_label>Patients with Non-alcoholic fatty liver disease</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Measurement of serum semaphorin concentrations</intervention_name>
    <description>Semaphorin concentration will be measured in patient sera by ELISA.</description>
    <arm_group_label>Controls</arm_group_label>
    <arm_group_label>Patients with Non-alcoholic fatty liver disease</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Identification of semaphorin gene polymorphisms</intervention_name>
    <description>Semaphorin genes will be sequenced to identify semaphorin gene polymorphisms associated with NAFLD.</description>
    <arm_group_label>Controls</arm_group_label>
    <arm_group_label>Patients with Non-alcoholic fatty liver disease</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        120 patients diagnosed with NAFLD and 40 healthy controls will be included.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients diagnosed with NAFLD according to current guidelines (AASLD, EASL)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Immunosuppression&#xD;
&#xD;
          -  Malignancies&#xD;
&#xD;
          -  Autoimmune diseases&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  HIV&#xD;
&#xD;
          -  Chronic viral hepatitis&#xD;
&#xD;
          -  Presence of other chronic liver disease (hemochromatosis, Wilson's disease, toxic&#xD;
             hepatitis, deficiency of alpha-1-antitrypsin, liver autoimmune disease)&#xD;
&#xD;
          -  Consumption of alcohol &gt; 20 g/day&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Neven Papic, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital for Infectious Diseases Zagreb</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Branimir Gjurasin, MD</last_name>
    <phone>+38512826222</phone>
    <email>bgjurasin@bfm.hr</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital for Infectious Diseases Zagreb</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Neven Papic, MD, PhD</last_name>
      <phone>+38512826222</phone>
      <email>npapic@bfm.hr</email>
    </contact>
    <investigator>
      <last_name>Neven Papic, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Branimir Gjurasin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anita Atelj, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Juraj Krznaric, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maja Mijic, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ivana Stromar Knezevic, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Croatia</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 16, 2020</study_first_submitted>
  <study_first_submitted_qc>September 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 5, 2020</study_first_posted>
  <last_update_submitted>September 29, 2020</last_update_submitted>
  <last_update_submitted_qc>September 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

